Cell therapy specialist ReNeuron Group PLC (LON:RENE) told investors its therapeutic programmes are “progressing to plan”.
In an update ahead of the company’s annual meeting it confirmed it is putting the finishing touches to data packages that will be submitted as part of its application to start a US Phase III clinical trial using its CTX cells to treat stroke victims.
WATCH: It's 'all systems go' as ReNeuron gears up for Phase III stroke disability study
The submission will be made in the final quarter of this year. The study is expected to get underway in 2018 with the results due in 2020.
ReNeuron chief executive Olav Hellebø will also tell shareholders the firm’s US Phase I/II clinical trial of its human retinal progenitor cell (hRPC) therapy for the degenerative eye disease retinitis pigmentosa (RP) is “proceeding well”.
All nine patients in the Phase I element of this study have now been treated and short term safety and tolerability data is expected in the final quarter of this year.
READ: ReNeuron Group upbeat as it progresses on all stem cell fronts
The company said it is currently finalising the “relevant protocols” to enlarge the Phase II clinical development plan.
It expects additional read-outs from the RP phase clinical trial in the second half of 2018, with further Phase II efficacy data from a larger group of patients expected in mid-2019.
It also plans a Phase II trial of cell treatments in cone-rod dystrophy, a rare eye disorder.